Scarica l'app Stockscreener
1.58
4.82%
-0.08
Precedente Chiudi:
$1.66
Aprire:
$1.65
Volume 24 ore:
533.40K
Relative Volume:
0.70
Capitalizzazione di mercato:
$99.87M
Reddito:
$139.77M
Utile/perdita netta:
$-97.62M
Rapporto P/E:
-1.00
EPS:
-1.58
Flusso di cassa netto:
$-61.71M
1 W Prestazione:
-17.28%
1M Prestazione:
-11.24%
6M Prestazione:
-9.71%
1 anno Prestazione:
-59.17%
Intervallo 1D:
$1.54
$1.69
Intervallo di 1 settimana:
$1.54
$1.94
Portata 52W:
$0.9897
$5.10
Macrogenics Inc Stock (MGNX) Company Profile
Nome
Macrogenics Inc
Settore
Industria
Telefono
301-251-5172
Indirizzo
9704 MEDICAL CENTER DRIVE, Rockville, MD
Confronta MGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.58 | 104.92M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2024-11-07 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-31 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-05-10 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Downgrade | Stifel | Buy → Hold |
| 2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
| 2024-04-26 | Iniziato | B. Riley Securities | Buy |
| 2024-04-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-03-04 | Reiterato | BTIG Research | Buy |
| 2024-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-22 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-11-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-02-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-04 | Iniziato | SMBC Nikko | Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Aggiornamento | Barclays | Underweight → Overweight |
| 2020-12-22 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-03 | Downgrade | Citigroup | Buy → Neutral |
| 2020-06-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2019-12-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Guggenheim | Neutral |
| 2019-02-07 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-02-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-02-06 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Downgrade | Citigroup | Neutral → Sell |
| 2018-12-10 | Downgrade | Raymond James | Outperform → Underperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-05-31 | Iniziato | Evercore ISI | Outperform |
| 2018-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-31 | Iniziato | Raymond James | Outperform |
Mostra tutto
Macrogenics Inc Borsa (MGNX) Ultime notizie
HC Wainwright & Co. Reiterates MacroGenics (MGNX) Neutral Recommendation - Nasdaq
Can MacroGenics Inc. stock hit record highs againEarnings Risk Report & Real-Time Volume Spike Alerts - newser.com
Will MacroGenics Inc. stock rally after Fed decisionsMarket Growth Report & Safe Capital Growth Tips - newser.com
Will MacroGenics Inc. stock recover after recent dropCEO Change & Daily Entry Point Alerts - newser.com
MGNX: HC Wainwright Reiterates Neutral Rating with $2.00 Price Target | MGNX Stock News - GuruFocus
Technical analysis overview for MacroGenics Inc. stockJuly 2025 Review & Daily Chart Pattern Signals - newser.com
How to escape a deep drawdown in MacroGenics Inc.Trade Ideas & Long-Term Investment Growth Plans - newser.com
Ranking MacroGenics Inc. among high performing stocks via tools2025 Key Highlights & Entry Point Confirmation Alerts - newser.com
What MACD and RSI say about MacroGenics Inc.Weekly Volume Report & High Yield Equity Trading Tips - newser.com
Applying sector rotation models to MacroGenics Inc.July 2025 PreEarnings & AI Enhanced Trading Alerts - newser.com
How MacroGenics Inc. stock performs in high volatility marketsQuarterly Performance Summary & Fast Momentum Entry Tips - newser.com
Combining machine learning predictions for MacroGenics Inc.Short Setup & AI Powered Market Trend Analysis - newser.com
Chart overlay techniques for tracking MacroGenics Inc.2025 Risk Factors & AI Based Trade Execution Alerts - newser.com
How to use Fibonacci retracement on MacroGenics Inc.July 2025 Closing Moves & Proven Capital Preservation Tips - newser.com
Will MacroGenics Inc. stock maintain growth storyEarnings Growth Report & Community Verified Swing Trade Signals - newser.com
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Can MacroGenics Inc. stock sustain market leadership2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
Detecting support and resistance levels for MacroGenics Inc.2025 Volatility Report & Safe Capital Preservation Plans - newser.com
Will MacroGenics Inc. stock benefit from automationWeekly Investment Recap & Entry Point Confirmation Signals - newser.com
MacroGenics’ MGD024 Study: A New Hope for Blood Cancer Treatment? - TipRanks
MacroGenics’ Lorigerlimab Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
MacroGenics (MGNX) Expected to Announce Earnings on Tuesday - MarketBeat
MacroGenics (NASDAQ:MGNX) Stock Price Crosses Above Fifty Day Moving AverageHere's Why - MarketBeat
Macrogenics Inc Azioni (MGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):